Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 5/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | GIPR | P48546 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | BCL9 | O00512 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6602227 | 0.93 | GCGR (0.37) | CHEK2ALDH1A1MAPTGCGRGIPR | |
| SCHEMBL6602511 | 0.91 | ALDH1A1 (0.37) | CHEK2ALDH1A1MAPTGCGRGIPR | |
| SCHEMBL6613906 | 0.90 | CHEK2 (0.38) | CHEK2CHEK1ALDH1A1MAPTGCGR | |
| SCHEMBL6806561 | 0.88 | CREBBP (0.37) | MAPTSLC6A9HPGDTRPM4 | |
| SCHEMBL6602793 | 0.86 | CHEK1 (0.38) | CHEK2CHEK1ALDH1A1MAPTGCGR | |
| SCHEMBL6602016 | 0.85 | HPGD (0.37) | MAPTSLC6A9HPGD | |
| SCHEMBL6606588 | 0.85 | TNFRSF1A (0.35) | CHEK2ALDH1A1MAPTGCGRGIPR | |
| SCHEMBL6805493 | 0.83 | TDP1 (0.36) | MAPTSLC6A9HPGD | |
| SCHEMBL6602641 | 0.83 | HSD17B1 (0.37) | ALDH1A1MAPTGCGRGIPRHDAC1 | |
| SCHEMBL6607126 | 0.83 | GCGR (0.37) | CHEK2ALDH1A1MAPTGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-1432689-A1 | PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | Bayer Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027074-A1 | PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | MKI67, CDK4, FLT4 | CHEK2 957/4885CHEK1 653/4885ALDH1A1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.